ASTCT Practice Guidelines "Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy"

Program Description: Articles designated for CME credit are designed to be the next step in the process of translating clinically relevant, evidence-based recommendations into clinical practice. This will be accomplished through a series of questions specifically designed to test that readers have the tools needed to translate recommendations for diagnostic and therapeutic clinical care into clinical practice. Post-test questions will assess if practitioners have understood the most important recommendations available for the diagnosis and treatment of pulmonary diseases, critical illness, and sleep disorders, and are able to implement them into clinical practice. Each Journal CME activity consists of the full-text article, a post-test quiz, and a course evaluation. Each CME activity should take approximately 1 hour to complete. This is an online-only activity.

Article Description: With improved safety profile of CAR-T cell products, feasibility and safety of CAR-T cell therapy in the outpatient setting has become more available and standard of care in many institutions. This expert panel opinion paper from ASTCT provides considerations for successful outpatient CAR-T therapy programs.  

Learning Objectives: Upon completion of this course, the learners should be able to:

1. Distinguish decision making aspects about treatment in the outpatient setting, including assessing the risk profile of the specific patient and CAR-T cell product.
2. Explain that with correct tools and infrastructure outpatient CAR-T cell therapy is feasible for most of the patients 

Target Audience: This educational activity is intended for physicians, nurses, and other members of the health care team who care for patients undergoing hematopoietic stem cell transplantation.

Instructions for Participation and Requesting Credit: There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CME information, completing the activity, and completing the post-test and evaluation form. A posttest score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed. Once the test is passed, participants will be asked to fill out a program evaluation in order to download the CME Certificate. The CME Certificate will be available for download at the same link in the ASTCT Learning Center once the evaluation has been submitted. By completing this evaluation, you grant ASTCT permission to report your participation to the ACCME and that you grant the ACCME permission to share the learner data that ASTCT reports with the learner's state medical licensing board(s) and/or specialty certifying board(s). If you have any concerns about these permissions, please email info@astct.org.

Technical Requirements: This site and its activities are best viewed using the latest versions of the Chrome, Edge, Firefox and Safari browsers. Additionally, this site and its activities are best viewed using the latest Operating System for your device.

If you have any questions about this course, please reach out to info@astct.org.

ACCREDITED PROVIDER 

This activity is provided by The American Society for Transplantation and Cellular Therapy

Accreditation Statement: In support of improving patient care, The American Society for Transplantation and Cellular Therapy is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Society for Transplantation and Cellular Therapy designates this journal-based activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Release date: March 14, 2024

Expiration date: November 1, 2024

Estimated time of completion: 1 hour

Learning Objectives: Upon completion of this activity, the learners should be able to:

1. Distinguish decision making aspects about treatment in the outpatient setting, including assessing the risk profile of the specific patient and CAR-T cell product.
2. Explain that with correct tools and infrastructure outpatient CAR-T cell therapy is feasible for most of the patients 

Target Audience: This educational activity is intended for physicians, nurses, and other members of the health care team who care for patients undergoing hematopoietic stem cell transplantation.

Planning Faculty and Disclosures: In accordance with the ACCME Standards for Commercial Support the American Society for Transplantation and Cellular Therapy (ASTCT) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. ASTCT resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.

• Azada Ibrahimova, MD, Cincinnati Children's Hospital Medical Center – reported no relevant financial relationships. 
• Tania Jain, MBBS, Johns Hopkins University – reported current grant and research support from Kartos Therapeutics, Incyte, and Bristol Myers Squibb.
• Kyra Newman, ASTCT - reported no relevant financial relationships.

Commercial Support Acknowledgment: This activity did not receive commercial support.

Disclaimer: ASTCT presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. ASTCT assumes no liability for the information herein.

Disclosure of Unlabeled Use: ASTCT requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. ASTCT does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.